Day: September 5, 2025

TAINAN, Taiwan, Sept. 05, 2025 (GLOBE NEWSWIRE) — Himax Technologies, Inc. (“Himax” or “Company”) (Nasdaq: HIMX), an industry leader in fabless display driver ICs and other semiconductors, today announced it will showcase its industry leading comprehensive automotive display portfolio in addition to other state-of-the-art technologies at the upcoming SID Vehicle Displays and Interfaces Symposium, taking place September 9 – 10, 2025, at Huntington Place in Detroit, Michigan. Organized by the Society for Information Display (SID), the symposium is one of the premier international events dedicated to automotive display and human–machine interface (HMI) technologies. The automotive display market is undergoing a major transformation, marked by increasing numbers, larger sizes, and greater complexity of displays in both electric and...

Press contact:Antara NandyTel.: +91 9674515119Email: antara.nandy@capgemini.com Six in 10 organizations expect AI to be an active team member or supervisor to other AI in the next 12 months Enterprise Gen AI adoption has grown fivefold in the last two years, outpacing enterprise readiness and intensifying challenges around cost, workforce adaptation, and governance Paris, September 5, 2025 – The latest Capgemini Research Institute report published today, ‘Harnessing the value of AI: Unlocking scalable advantage,’ suggests that generative AI (Gen AI) is rapidly moving into the mainstream, with enterprise adoption and investment accelerating at pace. According to the report, nearly 6 in 10 organizations are expected to have AI as an active team member or a supervisor for other AI within the next 12 months – up from 44% currently. Despite...

Press release                                                                                                    Paris, 5 September 2025Crédit Agricole Assurances S.A. announces redemption of its Undated Subordinated Resettable Notes issued on 14 October 2014 (ISIN: FR0012222297) Crédit Agricole Assurances S.A. (the “Issuer”) announces today the redemption (the “Redemption”) with effect on 14 October 2025 (the “Redemption Date”) of all of its outstanding Undated Subordinated Resettable Notes issued on 14 October 2014 for an initial aggregate principal amount of €750,000,000 (ISIN: FR0012222297) (the “Notes”) pursuant to Condition 6.2 (Optional Redemption from the First Call Date) of the terms and conditions of the Notes (the “Terms and Conditions”) included in the prospectus which was granted the visa n°14-546 by the Autorité des marchés...

Sampo plc, stock exchange release, 5 September 2025 at 8:30 am EEST Sampo plc’s share buybacks 4 September 2025                                                    On 4 September 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  5,428 9.67 AQEU    115,355 9.67 CEUX  37,548 9.67 TQEX  175,332 9.67 XHELTOTAL 333,663 9.67  * rounded to two decimals                      On 6 August 2025, Sampo announced a share buyback programme of up to a maximum of EUR 200 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation...

Multi-phase program to standardize treatment, generate real-world evidence and explore AI-powered tools to improve outcomes for hypertension patientsAllschwil, Switzerland & Radnor, Philadelphia – September 5, 2025Idorsia Ltd (SIX: IDIA) announces a first-of-its-kind initiative with the Stanford Hypertension Center and Duke Heart Center to launch IMPACT-HTN, a new three-phase program to transform and modernize the management of difficult-to-control hypertension. Patients requiring multiple medications for difficult-to-control hypertension face increasing challenges with care coordination, evaluation of underlying causes, and worsening outcomes. The initiative, led by Dr. Vivek Bhalla of the Stanford University School of Medicine and Dr. Sreekanth Vemulapalli of Duke University School of Medicine, is expected to generate real-world...

In AVONELLE-X, the largest long-term extension trial in nAMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end1 Over 60% of people with a difficult-to-treat form of nAMD showed no signs of damaging lesions in the SALWEEN study, and clinically meaningful vision improvements were observed2 Vabysmo was well tolerated with a consistent long-term safety profile in nAMD in both studiesBasel, 05 September 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new data from the AVONELLE-X and SALWEEN studies of Vabysmo® (faricimab),1,2 presented at the 25th Euretina Congress in Paris, France. Data from the open-label AVONELLE-X study reinforce the efficacy, safety and durability of Vabysmo over four years in neovascular or “wet” age-related macular degeneration...

Micron joins White House initiative to prepare the next generation for AI leadership BOISE, Idaho, Sept. 04, 2025 (GLOBE NEWSWIRE) — Micron Technology, Inc. (Nasdaq: MU) is proud to announce its commitment to the White House’s Pledge to America’s Youth: Investing in AI Education, a national initiative aimed at preparing young Americans to lead in an AI-powered future. Over the next four years, Micron will empower more than 40,000 learners and educators through a comprehensive suite of AI education programs, hands-on learning experiences and employee-led mentorship. This pledge reflects Micron’s deep belief that access to AI education is essential to securing America’s technological leadership. Specifically, Micron’s commitments include:Incorporating AI lessons and activities in 100% of our signature programs – such as Chip Camps,...

TORONTO, Sept. 04, 2025 (GLOBE NEWSWIRE) — Future Mineral Resources Inc. (formerly Sulliden Mining Capital Inc.) (“Future Mineral” or the “Company”) (TSX: SMC) is pleased to announce that (i) it has changed its name from Sulliden Mining Capital Inc. to Future Mineral Resources Inc. and (ii) the board of directors of the Company has authorized the implementation of a consolidation (the “Consolidation”) of the Company’s common shares (the “Shares”) on the basis of one post-Consolidation Share for every 10 pre-Consolidation Shares, each effective September 5, 2025. Future Mineral currently has 166,875,979 Shares issued and outstanding. Following completion of the Consolidation, the Company will have approximately 16,687,597 Shares issued and outstanding. No fractional Shares will be issued pursuant to the Consolidation; fractional...

Not for release to U.S. wire services or for distribution in the United States VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) — Marimaca Copper Corp. (TSX: MARI) (ASX: MC2) (“Marimaca” or the “Company”) announces that further to the previously announced best-efforts brokered placement in Australia and select other jurisdictions outside of Australia, except for Canada, the Company will issue an aggregate of 8,247,423 Chess Depositary Interests (“CDI”) at a price of A$9.70(1) per CDI for gross proceeds of approximately A$80,000,000 or approximately C$72,080,000 (the “Placement”). The net proceeds from the Placement will be used for detailed design and engineering and project related workstreams at the Marimaca Oxide Deposit (the “MOD”), exploration at the Pampa Medina Project and Marimaca sulphide target, and for general...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the 2025 World Conference on Lung Cancer (“WCLC”) taking place on September 6-9, 2025 in Barcelona, Spain, and the Chinese Society of Clinical Oncology (“CSCO”) Annual Meeting 2025, taking place on September 10-14, 2025 in Jinan, China. Updated analysis from savolitinib’s SACHI, SAVANNAH and a Phase IIIb confirmatory study in non-small cell lung cancer (“NSCLC”) patients will be presented at WCLC 2025. Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”) being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca....